Treatment concept successfully translated into human patients

Keywords

Immunotherapy / neuroprotection failure / translation block / bench-to-bedside translation

References

[1] Hermann DM. Cutting edges in neuroscience to exceed borders. Explor Neurosci. 2022;1:1–3.

[2] Jellinger KA. Recent developments and future perspectives of neuropathology. Explor Neurosci. 2022;1:54–60.

[3] Lecanemab confirmatory phase 3 Clarity AD study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer’s disease [Internet]. Biogen; c2023 [cited 2022 Nov 11]. Available from: https://investors.biogen.com/news-releases/news-release-details/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary

[4] van Dyck CHSwanson CJAisen PBateman RJChen CGee Met al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.

[5] Aducanumab (marketed as Aduhelm) information [Internet]. [cited 2022 Nov 11]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information

[6] Knopman DSJones DTGreicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17:696–701.

[7] Arnold C. Post-hoc analysis could give new life to the Alzheimer’s drug aducanumab. Nat Med. 2020;[Epub ahead of print].

[8] Selkoe DJHardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.